Suppr超能文献

血管性痴呆的药物治疗:分子机制视角

Pharmacological Treatment of Vascular Dementia: A Molecular Mechanism Perspective.

作者信息

Kuang Huang, Zhou Zhi-Feng, Zhu Yu-Ge, Wan Zhi-Kai, Yang Mei-Wen, Hong Fen-Fang, Yang Shu-Long

机构信息

1Department of Physiology, College of Medicine, Nanchang University, Nanchang, China.

2Department of Nurse, Nanchang University Hospital, Nanchang 330006, Jiangxi, China.

出版信息

Aging Dis. 2021 Feb 1;12(1):308-326. doi: 10.14336/AD.2020.0427. eCollection 2021 Feb.

Abstract

Vascular dementia (VaD) is a neurodegenerative disease, with cognitive dysfunction attributable to cerebrovascular factors. At present, it is the second most frequently occurring type of dementia in older adults (after Alzheimer's disease). The underlying etiology of VaD has not been completely elucidated, which limits its management. Currently, there are no approved standard treatments for VaD. The drugs used in VaD are only suitable for symptomatic treatment and cannot prevent or reduce the occurrence and progression of VaD. This review summarizes the current status of pharmacological treatment for VaD, from the perspective of the molecular mechanisms specified in various pathogenic hypotheses, including oxidative stress, the central cholinergic system, neuroinflammation, neuronal apoptosis, and synaptic plasticity. As VaD is a chronic cerebrovascular disease with multifactorial etiology, combined therapy, targeting multiple pathophysiological factors, may be the future trend in VaD.

摘要

血管性痴呆(VaD)是一种神经退行性疾病,其认知功能障碍归因于脑血管因素。目前,它是老年人中第二常见的痴呆类型(仅次于阿尔茨海默病)。VaD的潜在病因尚未完全阐明,这限制了其治疗。目前,尚无批准用于VaD的标准治疗方法。用于VaD的药物仅适用于对症治疗,无法预防或减少VaD的发生和进展。本综述从各种致病假说中指定的分子机制角度,包括氧化应激、中枢胆碱能系统、神经炎症、神经元凋亡和突触可塑性,总结了VaD药物治疗的现状。由于VaD是一种病因多因素的慢性脑血管疾病,针对多种病理生理因素的联合治疗可能是VaD未来的发展趋势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验